Abstract Despite the enormous therapeutic potential of immune checkpoint blockade (ICB), it benefits only a small subset of patients. Some chemotherapeutics can switch ‘immune-cold’ tumours
Highlights •High TMB correlates with efficacy of PD-1 plus CTLA-4 blockade in NSCLC •TMB and PD-L1 are independent variables •In multivariate analysis, TMB associated most
It sounds paradoxical, but chimeric antigen receptor (CAR) T cells can be more easy-going and more effective at killing cancer cells. Engineering a lackadaisical but